Two newly designed experimental compounds called MAHS-3 and MAHS-4 stopped cancer cell growth in approximately 63% of laboratory tests, matching the effectiveness of methotrexate, a standard cancer drug. According to Gram Research analysis, these compounds worked by blocking enzymes cancer cells need to copy their DNA and also triggered cancer cells to self-destruct and prevented spreading. However, these are very early-stage laboratory discoveries that have not been tested in animals or humans.
Scientists have created two new experimental drugs that may help fight cancer by stopping cancer cells from making the DNA they need to grow. In laboratory tests, these drugs called MAHS-3 and MAHS-4 worked about as well as a common cancer medicine called methotrexate. The drugs also triggered cancer cells to self-destruct and prevented them from spreading to other parts of the body. According to Gram Research analysis, these compounds represent an early-stage discovery that could eventually lead to new cancer treatments, though much more testing in animals and humans is needed before they could be used as actual medicines.
Key Statistics
A 2026 laboratory study of 60 cancer cell types found that two experimental compounds, MAHS-3 and MAHS-4, stopped cancer cell growth in 62.79% and 63.37% of cases respectively, comparable to methotrexate’s 65.60% effectiveness.
According to research published in Bioorganic Chemistry in 2026, the experimental compound MAHS-4 showed 1.5 to 2.5 times greater potency at blocking the TS enzyme compared to 5-FU, a drug currently used in cancer treatment.
A 2026 analysis of two experimental cancer compounds found they triggered multiple forms of cancer cell death including programmed cell death (apoptosis) and autophagy, while also preventing cancer cells from migrating and spreading to other areas.
The Quick Take
- What they studied: Whether two newly designed chemical compounds could stop cancer cells from growing by blocking the enzymes that cancer cells use to copy their DNA.
- Who participated: Laboratory tests using 60 different types of cancer cells from the National Cancer Institute, including leukemia, lung, kidney, prostate, and breast cancer cells.
- Key finding: Two compounds named MAHS-3 and MAHS-4 stopped cancer cell growth in about 63% of cases, matching the effectiveness of methotrexate, a drug already used to treat cancer.
- What it means for you: This is very early research in a laboratory setting. These compounds are not yet medicines and have not been tested in humans. If future studies continue to show promise, they might eventually become new cancer treatment options, but that would take many years of additional research.
The Research Details
Researchers designed and created 11 new chemical compounds based on a specific molecular structure. They then tested these compounds against 60 different types of cancer cells grown in laboratory dishes to see which ones were most effective at stopping cancer growth. The two best-performing compounds, MAHS-3 and MAHS-4, were studied in more detail to understand how they work and whether they meet basic requirements for becoming drugs.
The scientists used several testing methods to evaluate the compounds. They measured how well the compounds blocked two specific enzymes that cancer cells need to survive and grow. They also examined what happened inside cancer cells when exposed to these compounds, looking for signs that the cells were dying or stopping their growth. Additionally, they used computer modeling to understand how the compounds fit into the target enzymes and what parts of the molecules were most important for their activity.
This type of research is called ‘hit identification’ in drug development—it’s the very first step where scientists find promising chemical candidates that might eventually become medicines. The compounds were also checked against standard rules that predict whether a chemical could potentially become a safe, effective drug.
Understanding how to block the specific enzymes that cancer cells depend on is important because cancer cells need these enzymes to make new DNA and divide rapidly. By targeting these enzymes differently than existing drugs, researchers might be able to create treatments that work better or have fewer side effects. This research also shows that the new compounds work through multiple mechanisms—they don’t just stop growth, but also trigger cancer cells to self-destruct and prevent them from spreading.
This is laboratory research using cancer cells in dishes, which is the earliest stage of drug development. The compounds showed consistent results across many different cancer types, which is a positive sign. However, these results do not tell us whether the compounds would work in living animals or humans, whether they would be safe, or how the body would process them. The compounds were tested against established cancer drugs, which provides a useful comparison point. The research was published in a peer-reviewed scientific journal, meaning other experts reviewed the work before publication.
What the Results Show
The two lead compounds, MAHS-3 and MAHS-4, stopped the growth of cancer cells in about 63% of cases, which was comparable to methotrexate, a standard cancer drug used in clinics today. These compounds worked against a broad range of cancer types, including leukemia, lung cancer, kidney cancer, prostate cancer, and breast cancer. The compounds were effective at relatively low concentrations, with half-maximal growth inhibition occurring at concentrations ranging from 0.276 to 85.2 micromolar depending on the cancer type.
When researchers examined the two compounds’ effects on the target enzymes, MAHS-3 and MAHS-4 showed moderate ability to block the DHFR enzyme but were particularly effective at blocking the TS enzyme—about 1.5 to 2.5 times more potent than a drug called 5-FU that is currently used in cancer treatment. This suggests the compounds’ main anti-cancer effect comes from blocking TS rather than DHFR.
The compounds triggered cancer cell death through multiple pathways. They caused cancer cells to pause at a specific stage of cell division (the G2/M stage), activated proteins that trigger programmed cell death (apoptosis), and induced autophagy, which is another form of cell death. Importantly, the compounds also prevented cancer cells from migrating and spreading, which is a key feature of aggressive cancers.
Additional testing revealed that the compounds increased levels of nitric oxide inside cancer cells, which may contribute to their anti-cancer effects. The compounds also induced autophagy-related cell death, meaning they triggered cancer cells to essentially eat themselves. Computer modeling showed that both compounds fit well into the target enzyme binding sites and identified specific parts of the molecules that could be improved in future versions. The compounds met standard criteria for drug-likeness, meaning they have chemical properties that suggest they could potentially be developed into actual medicines.
The compounds represent a new approach to blocking cancer-related enzymes. While methotrexate has been used for decades and works by blocking DHFR, these new compounds appear to work more effectively by targeting TS. The enhanced TS inhibition compared to 5-FU, another standard cancer drug, suggests these compounds might offer advantages over existing treatments. However, this is very early research, and direct comparisons in living systems have not yet been made.
This research was conducted entirely in laboratory dishes using cancer cells grown outside the body. Results in cell cultures do not always translate to living organisms. The compounds have not been tested in animals or humans, so we don’t know if they would be safe or effective in real patients. The study did not examine how the body would absorb, process, or eliminate these compounds. The exact mechanisms of how these compounds work are not completely understood. The compounds showed moderate, not complete, inhibition of the DHFR enzyme, which may limit their effectiveness. Much additional research and optimization would be needed before these compounds could be considered for human testing.
The Bottom Line
These compounds should not be used as treatments—they are experimental chemicals in very early stages of research. For patients with cancer, current approved treatments recommended by oncologists remain the appropriate choice. For researchers and pharmaceutical companies, these compounds represent interesting starting points for drug development that warrant further investigation, optimization, and testing in animal models.
Cancer researchers and pharmaceutical companies developing new treatments should be interested in these findings as a potential starting point for drug development. Patients with cancer should be aware that while new drug candidates are constantly being discovered, the journey from laboratory discovery to approved medicine typically takes 10-15 years. People interested in cancer biology and drug development may find this research interesting as an example of how new medicines are discovered.
This is a preliminary discovery stage. If development continues, animal testing would typically take 3-6 years. If successful in animals, human clinical trials could begin, which would take another 5-10 years. An actual approved medicine based on this research, if it happens at all, would likely not be available for at least 10-15 years.
Frequently Asked Questions
Are these new cancer drugs available to patients now?
No. These compounds are experimental chemicals tested only in laboratory dishes with cancer cells. They have not been tested in animals or humans and are not approved medicines. Patients should continue using cancer treatments recommended by their oncologists.
How do these new compounds work differently than existing cancer drugs?
These compounds primarily block an enzyme called TS that cancer cells need to copy their DNA, and they work about 1.5 to 2.5 times better than current TS-blocking drugs. They also trigger cancer cells to self-destruct through multiple pathways simultaneously.
When might these compounds become actual cancer medicines?
If development continues successfully, animal testing would take 3-6 years, followed by human clinical trials lasting 5-10 years. An approved medicine, if it reaches that stage, would likely not be available for 10-15 years or more.
What types of cancer did these compounds work against?
In laboratory tests, the compounds showed activity against leukemia, lung cancer, kidney cancer, prostate cancer, and breast cancer cells, suggesting they might have broad anti-cancer potential across multiple cancer types.
Why is blocking these specific enzymes important for cancer treatment?
Cancer cells need these enzymes to make new DNA and divide rapidly. By blocking them, the compounds stop cancer cell growth and trigger the cells to die, which is the goal of cancer therapy.
Want to Apply This Research?
- Users interested in cancer research developments could track ’emerging cancer therapies’ by setting reminders to review quarterly updates on new drug candidates moving through clinical trial phases, noting which compounds advance from laboratory to animal testing stages.
- Users could use the app to stay informed about cancer prevention and early detection by tracking participation in recommended cancer screenings (mammograms, colonoscopies, etc.) and maintaining lifestyle factors that reduce cancer risk, such as exercise frequency and vegetable intake.
- Create a ‘cancer research tracker’ that allows users to bookmark and monitor specific drug candidates as they progress through development stages, receiving notifications when new clinical trial results are published or when compounds advance to human testing phases.
This research describes experimental compounds tested only in laboratory cell cultures and represents very early-stage drug discovery. These compounds are not approved medicines and have not been tested in animals or humans. They should not be considered as treatments for cancer. Patients with cancer should consult with their oncologists about appropriate, approved treatment options. This article is for informational purposes only and should not be used as medical advice. The progression from laboratory discovery to approved medicine typically takes 10-15 years and many compounds that show promise in early research never become actual medicines.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.